biperiden has been researched along with Chronic Disease in 10 studies
Biperiden: A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.
biperiden : A member of the class of piperidines that is N-propylpiperidine in which the methyl hydrogens have been replaced by hydroxy, phenyl, and 5-norbornen-2-yl groups. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all forms of Parkinson's disease.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Efficacy of ziprasidone (80-160 mg/d) and olanzapine 10-20 mg was measured using the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impression (CGI) Scale, the Calgary Depression Scale for Schizophrenia (CDSS), and the Heinrich Quality of Life Scale (HQLS); tolerability assessments included laboratory assessments, body weight, and electroencephalogram." | 9.15 | Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. ( Buitelaar, JK; Grootens, KP; Kahn, RS; Peuskens, J; Sabbe, BG; Thys, E; van Veelen, NM; Verkes, RJ, 2011) |
| " Efficacy of ziprasidone (80-160 mg/d) and olanzapine 10-20 mg was measured using the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impression (CGI) Scale, the Calgary Depression Scale for Schizophrenia (CDSS), and the Heinrich Quality of Life Scale (HQLS); tolerability assessments included laboratory assessments, body weight, and electroencephalogram." | 5.15 | Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. ( Buitelaar, JK; Grootens, KP; Kahn, RS; Peuskens, J; Sabbe, BG; Thys, E; van Veelen, NM; Verkes, RJ, 2011) |
| "Penfluridol has the clear practical advantage of being the only long-acting drug for oral administration so far available." | 1.26 | Controlled trial of penfluridol and thiothixene in the maintenance treatment of chronic schizophrenic syndromes. ( Edenius, B; Jacobsson, L; Kettner, B; Magnusson, KE; Mattsson, B; Perris, C; Rapp, W; Villemoes, P; Von Knorring, L, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (40.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bittencourt, S | 1 |
| Ferrazoli, E | 1 |
| Valente, MF | 1 |
| Romariz, S | 1 |
| Janisset, NRLL | 1 |
| Macedo, CE | 1 |
| Antonio, BB | 1 |
| Barros, V | 1 |
| Mundim, M | 1 |
| Porcionatto, M | 1 |
| Aarão, MC | 1 |
| Miranda, MF | 1 |
| Rodrigues, AM | 1 |
| de Almeida, AG | 1 |
| Longo, BM | 1 |
| Mello, LE | 1 |
| Grootens, KP | 1 |
| van Veelen, NM | 1 |
| Peuskens, J | 1 |
| Sabbe, BG | 1 |
| Thys, E | 1 |
| Buitelaar, JK | 1 |
| Verkes, RJ | 1 |
| Kahn, RS | 1 |
| Silver, H | 1 |
| Geraisy, N | 1 |
| Meszaros, K | 1 |
| Lenzinger, E | 1 |
| Hornik, K | 1 |
| Schönbeck, G | 1 |
| Hatzinger, R | 1 |
| Langer, G | 1 |
| Sieghart, W | 1 |
| Aschauer, HN | 1 |
| Higuchi, H | 1 |
| Kamata, M | 1 |
| Yoshimoto, M | 1 |
| Shimisu, T | 1 |
| Hishikawa, Y | 1 |
| Jacobsson, L | 1 |
| Von Knorring, L | 1 |
| Mattsson, B | 1 |
| Perris, C | 1 |
| Rapp, W | 1 |
| Edenius, B | 1 |
| Kettner, B | 1 |
| Magnusson, KE | 1 |
| Villemoes, P | 1 |
| Westphal, KP | 1 |
| Grözinger, B | 1 |
| Diekmann, V | 1 |
| Scherb, W | 1 |
| Reess, J | 1 |
| Leibing, U | 1 |
| Kornhuber, HH | 1 |
| Klett, CJ | 1 |
| Caffey, E | 1 |
| Simpson, GM | 1 |
| Beckles, D | 1 |
| Isalski, Z | 1 |
| Lee, JH | 1 |
| Kurland, AA | 1 |
| Dim, BH | 1 |
| Olsson, JE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Biperiden for Prevention of Epilepsy in Patients With Traumatic Brain Injury[NCT04945213] | Phase 3 | 312 participants (Anticipated) | Interventional | 2023-01-10 | Recruiting | ||
| A Multicenter, Double-Blind, Randomized Trial Of Ziprasidone (80 - 160 Mg) Versus Olanzapine (10 - 20 Mg) In Patients With Recent-Onset Schizophrenia, Schizoaffective And Schizophreniform Disorder.[NCT00145444] | Phase 3 | 100 participants | Interventional | 2003-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for biperiden and Chronic Disease
| Article | Year |
|---|---|
Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.
Topics: Adult; Alanine Transaminase; Antipsychotic Agents; Aspartate Aminotransferases; Basal Ganglia Diseas | 2011 |
No difference in the effect of biperiden and amantadine on negative symptoms in medicated chronic schizophrenic patients.
Topics: Adult; Amantadine; Basal Ganglia Diseases; Biperiden; Chronic Disease; Cross-Over Studies; Dopamine | 1995 |
Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients.
Topics: Adult; Aged; Anti-Dyskinesia Agents; Antipsychotic Agents; Basal Ganglia Diseases; Biperiden; Chroni | 1997 |
Panic attacks in patients with chronic schizophrenia: a complication of long-term neuroleptic treatment.
Topics: Adult; Antipsychotic Agents; Biperiden; Chlorpromazine; Chronic Disease; Depression; Female; Humans; | 1999 |
Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics.
Topics: 1-Propanol; Adult; Antiparkinson Agents; Basal Ganglia Diseases; Benztropine; Biperiden; Chronic Dis | 1972 |
Some methodological considerations in the evaluation of drug-induced extrapyramidal disorders: a study of Ex10-029, a new morphanthridine derivative.
Topics: Adult; Antiparkinson Agents; Basal Ganglia Diseases; Biperiden; Chronic Disease; Clinical Trials as | 1972 |
4 other studies available for biperiden and Chronic Disease
| Article | Year |
|---|---|
Modification of the natural progression of epileptogenesis by means of biperiden in the pilocarpine model of epilepsy.
Topics: Action Potentials; Animals; Autonomic Nervous System; Biperiden; Chronic Disease; Cytokines; Disease | 2017 |
Controlled trial of penfluridol and thiothixene in the maintenance treatment of chronic schizophrenic syndromes.
Topics: Adolescent; Adult; Aged; Biperiden; Chlorpromazine; Chronic Disease; Drug Evaluation; Female; Humans | 1976 |
Slower theta activity over the midfrontal cortex in schizophrenic patients.
Topics: Adult; Biperiden; Chronic Disease; Drug Therapy, Combination; Electroencephalography; Female; Fronta | 1990 |
The effectiveness of parenteral administration of fluphenazine decanoate in the treatment of chronic schizophrenics.
Topics: Administration, Oral; Adult; Biperiden; Chronic Disease; Female; Fluphenazine; Humans; Infusions, Pa | 1970 |